


Hydroxychloroquine safe, effective treatment for anogenital lichen sclerosis: Study

July 26 2024, by Lori Solomon



Hydroxychloroquine appears to be a safe and effective treatment option for anogenital lichen sclerosis that only has mild adverse effects, according to a study [published](#) online July 19 in the *International Journal*

of Dermatology.

Christeebella O. Akpala, from the Mayo Clinic in Rochester, Minnesota, and colleagues analyzed the demographic characteristics, clinicopathological features, [treatment response](#), and outcomes of 70 patients diagnosed with either anogenital or extragenital [lichen](#) sclerosis who received hydroxychloroquine therapy (2018 to 2023).

The researchers found that 36% of patients had a [connective tissue disorder](#), prompting [hydroxychloroquine](#) therapy. Of the 30 patients treated solely for lichen sclerosis, 21 showed a response, and nine had no response. The overall response among those with anogenital lichen sclerosis was 84.6% compared to 50% in extragenital lichen sclerosis. Four months was the median time to initial response. Adverse effects were mostly mild and were seen in 14.3% of patients.

"Hydroxychloroquine demonstrates promise as a therapeutic option for anogenital lichen sclerosis because of its favorable response rates and low incidence of adverse effects," the authors write. "However, further investigations, including larger-scale or prospective studies, are imperative to ascertain its definitive efficacy."

More information: Christeebella O. Akpala et al, Treatment of lichen sclerosis with hydroxychloroquine: a Mayo Clinic experience, *International Journal of Dermatology* (2024). [DOI: 10.1111/ijd.17394](https://doi.org/10.1111/ijd.17394)

© 2024 [HealthDay](#). All rights reserved.

Citation: Hydroxychloroquine safe, effective treatment for anogenital lichen sclerosis: Study (2024, July 26) retrieved 27 July 2024 from <https://medicalxpress.com/news/2024-07-hydroxychloroquine-safe-effective-treatment-anogenital.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.